Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences is favored because its casdatifan franchise has produced compelling ARC-20 signals across ccRCC, including 44% ORR and 14.5-month mPFS with cabozantinib, 50% cORR and 69% 12-month PFS with zimberelimab, and 35-month mOS in late-line monotherapy, supporting the view that HIF-2α inhibition can be differentiated across treatment lines. The 3Q26 update and October financing introduced some dilution, but the core PEAK-1 thesis remains intact, with enrollment on track, PEAK-20 and PEAK-21 advancing, and multiple 2027 catalysts that could further validate superior efficacy versus belzutifan-based benchmarks. Beyond oncology, the pipeline adds optionality through quemliclustat in 1L PDAC and immunology assets such as AB102, oral TNFi, CCR6, STAT6, CD89, and CD40L, giving the company a broad, catalyst-rich profile that strengthens its fundamental outlook.

Arcus Biosciences is taking its cas-based combinations into Ph 3 before dose exploration is complete, creating meaningful development risk that the selected dose could sacrifice efficacy, fail to match bidaily results, or reveal unexpected toxicities. The company is also leaning on EPO suppression as a differentiating biomarker, but that signal has not been rigorously validated against tumor response, weakening confidence in the scientific rationale. Because several key assets are concentrated in the adenosine pathway, any efficacy miss or safety liability there could materially reduce cash flow expectations and valuation, while competitive setbacks in rival adenosine programs would further pressure the investment case.